Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 86

1.

Novel Doxorubicin Derivatives: Synthesis and Cytotoxicity Study in 2D and 3D in Vitro Models.

Akasov R, Drozdova M, Zaytseva-Zotova D, Leko M, Chelushkin P, Marc A, Chevalot I, Burov S, Klyachko N, Vandamme T, Markvicheva E.

Adv Pharm Bull. 2017 Dec;7(4):593-601. doi: 10.15171/apb.2017.071. Epub 2017 Dec 31.

2.

A smart tumor targeting peptide-drug conjugate, pHLIP-SS-DOX: synthesis and cellular uptake on MCF-7 and MCF-7/Adr cells.

Song Q, Chuan X, Chen B, He B, Zhang H, Dai W, Wang X, Zhang Q.

Drug Deliv. 2016 Jun;23(5):1734-46. doi: 10.3109/10717544.2015.1028601. Epub 2015 Apr 8.

PMID:
25853477
3.
4.

Resveratrol enhances chemosensitivity of doxorubicin in multidrug-resistant human breast cancer cells via increased cellular influx of doxorubicin.

Kim TH, Shin YJ, Won AJ, Lee BM, Choi WS, Jung JH, Chung HY, Kim HS.

Biochim Biophys Acta. 2014 Jan;1840(1):615-25. doi: 10.1016/j.bbagen.2013.10.023. Epub 2013 Oct 24.

PMID:
24161697
5.
6.

Co-delivery of doxorubicin and P-gp inhibitor by a reduction-sensitive liposome to overcome multidrug resistance, enhance anti-tumor efficiency and reduce toxicity.

Tang J, Zhang L, Gao H, Liu Y, Zhang Q, Ran R, Zhang Z, He Q.

Drug Deliv. 2016 May;23(4):1130-43. doi: 10.3109/10717544.2014.990651. Epub 2014 Dec 10.

PMID:
25491241
7.

Nelfinavir targets multiple drug resistance mechanisms to increase the efficacy of doxorubicin in MCF-7/Dox breast cancer cells.

Chakravarty G, Mathur A, Mallade P, Gerlach S, Willis J, Datta A, Srivastav S, Abdel-Mageed AB, Mondal D.

Biochimie. 2016 May;124:53-64. doi: 10.1016/j.biochi.2016.01.014. Epub 2016 Feb 1.

PMID:
26844637
8.

Mesoporous silica nanoparticles loading doxorubicin reverse multidrug resistance: performance and mechanism.

Shen J, He Q, Gao Y, Shi J, Li Y.

Nanoscale. 2011 Oct 5;3(10):4314-22. doi: 10.1039/c1nr10580a. Epub 2011 Sep 5.

PMID:
21892492
9.

Establishment of 2D Cell Cultures Derived From 3D MCF-7 Spheroids Displaying a Doxorubicin Resistant Profile.

Nunes AS, Costa EC, Barros AS, de Melo-Diogo D, Correia IJ.

Biotechnol J. 2019 Apr;14(4):e1800268. doi: 10.1002/biot.201800268. Epub 2018 Oct 10.

PMID:
30242980
10.

Micelles of d-α-Tocopheryl Polyethylene Glycol 2000 Succinate (TPGS 2K) for Doxorubicin Delivery with Reversal of Multidrug Resistance.

Hao T, Chen D, Liu K, Qi Y, Tian Y, Sun P, Liu Y, Li Z.

ACS Appl Mater Interfaces. 2015 Aug 19;7(32):18064-75. doi: 10.1021/acsami.5b04995. Epub 2015 Aug 5.

PMID:
26214761
11.

Sensitization of multidrug-resistant malignant cells by liposomes co-encapsulating doxorubicin and chloroquine through autophagic inhibition.

Gao M, Xu Y, Qiu L.

J Liposome Res. 2017 Jun;27(2):151-160. doi: 10.1080/08982104.2016.1185731. Epub 2016 Jun 2.

PMID:
27250110
12.
14.

Effects of amiodarone, cyclosporin A, and PSC 833 on the cytotoxicity of mitoxantrone, doxorubicin, and vincristine in non-P-glycoprotein human small cell lung cancer cell lines.

van der Graaf WT, de Vries EG, Timmer-Bosscha H, Meersma GJ, Mesander G, Vellenga E, Mulder NH.

Cancer Res. 1994 Oct 15;54(20):5368-73.

15.

Breast cancer targeted chemotherapy based on doxorubicin-loaded bombesin peptide modified nanocarriers.

Wang C, Sun X, Wang K, Wang Y, Yang F, Wang H.

Drug Deliv. 2016 Oct;23(8):2697-2702. Epub 2015 Jul 23.

PMID:
26203692
16.

Pegylated phosphotidylethanolamine inhibiting P-glycoprotein expression and enhancing retention of doxorubicin in MCF7/ADR cells.

Wang J, Qu H, Jin L, Zeng W, Qin L, Zhang F, Wei X, Lu W, Zhang C, Liang W.

J Pharm Sci. 2011 Jun;100(6):2267-77. doi: 10.1002/jps.22461. Epub 2011 Jan 18.

PMID:
21246559
17.

Redox-responsive nanoparticles from the single disulfide bond-bridged block copolymer as drug carriers for overcoming multidrug resistance in cancer cells.

Wang YC, Wang F, Sun TM, Wang J.

Bioconjug Chem. 2011 Oct 19;22(10):1939-45. doi: 10.1021/bc200139n. Epub 2011 Sep 9.

PMID:
21866903
19.

Co-delivery of DOX and PDTC by pH-sensitive nanoparticles to overcome multidrug resistance in breast cancer.

Cheng X, Li D, Sun M, He L, Zheng Y, Wang X, Tang R.

Colloids Surf B Biointerfaces. 2019 May 20;181:185-197. doi: 10.1016/j.colsurfb.2019.05.042. [Epub ahead of print]

PMID:
31132609
20.

Reversing of multidrug resistance breast cancer by co-delivery of P-gp siRNA and doxorubicin via folic acid-modified core-shell nanomicelles.

Wu Y, Zhang Y, Zhang W, Sun C, Wu J, Tang J.

Colloids Surf B Biointerfaces. 2016 Feb 1;138:60-9. doi: 10.1016/j.colsurfb.2015.11.041. Epub 2015 Nov 25.

PMID:
26655793

Supplemental Content

Support Center